The National Medical Products Administration approved Dupixent as an add-on maintenance treatment for adults with ...

慢性阻塞性肺病（COPD）分为稳定期与急性加重期，慢阻肺急性加重期（AECOPD）的特征是患者呼吸系统症状急性恶化，超出了日常的变异，且需要改变药物治疗方案。AECOPD ...

Chronic obstructive lung disease, also known as chronic obstructive pulmonary disease (COPD), is a general term for a group ...

The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...

(Yicai) Sept. 30 -- AstraZeneca will strengthen its commitment to researching chronic and rare diseases in China, driving ...

The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary ...

Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing ...

MP Cariappa, Public Health Specialist, Advisor, Tata Trusts shares inputs on understanding chronic lung diseases. He is also ...

Key Takeaways Regeneron and Sanofi shares edged higher Friday after their drug to treat chronic obstructive pulmonary disease ...

Ohtuvayre (ensifentrine) is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase three and phosphodiesterase 4 (“PDE3 and PDE4”) that combines bronchodilator and non-steroidal ...

Regeneron REGN0.26%increase; green up pointing triangle Pharmaceuticals and Sanofi SAN 0.65%increase; green up pointing triangle have won U.S. Food and Drug Administration expanded approval of their ...